Kenneth Manning, MD
Medical Oncology · Fayetteville, NCNPI 1003870171
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 66.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $3,405 and has fallen 97.5% since, to $85 in 2025.
Across 68 payments — averaging $69.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Eisai Inc.$263
- Genentech USA, Inc.$203
- Servier Pharmaceuticals LLC$139
- Daiichi Sankyo Inc.$125
- Incyte Corporation$125
- plus $766 from 18 others
Across 44 payments — averaging $2039.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tolmar, Inc.$39K
- Pfizer$24K
- Genentech, Inc.$16K
- Boehringer Ingelheim$11K
- AbbVie$990
What the payments were for
- Consulting fees$2,30048%
- Travel & lodging$49010%
- Food & beverage$1,86039%
- Education$1082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $3,138 |
| Eisai Inc. | 3 | $263 |
| Genentech USA, Inc. | 4 | $203 |
| Servier Pharmaceuticals LLC | 1 | $139 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Incyte Corporation | 1 | $125 |
| Astellas Pharma US Inc | 1 | $120 |
| Pfizer | 19 | $99 |
| Johnson & Johnson | 1 | $85 |
| Bristol Myers Squibb | 3 | $56 |
| Heron Therapeutics, Inc. | 4 | $53 |
| Merck | 3 | $49 |
| Lexicon Pharmaceuticals, Inc. | 3 | $39 |
| Gilead | 2 | $37 |
| Amgen | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Sirtex Medical Inc | 3 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Array Biopharma Inc | 1 | $22 |
| GSK | 1 | $20 |
| Roche Diagnostics Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,758 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 29 | $404,469 |
| IbrancePalbociclib | 16 | $234,407 |
| TasignaNilotinib Hcl | 15 | $186,157 |
| Imatinib Mesylate | 13 | $22,241 |
| XareltoRivaroxaban | 22 | $21,823 |
| Exemestane | 19 | $6,899 |
| Anastrozole | 259 | $6,018 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 72 | $2,856 |
| Letrozole | 30 | $967 |
| Tamoxifen Citrate | 36 | $947 |
| Oxycodone Hcl | 12 | $427 |
| Hydroxyurea | 15 | $414 |
| Gabapentin | 25 | $274 |
| Alprazolam | 18 | $182 |
| Tramadol Hcl | 13 | $175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $120 | $404,46929 claims |
| PfizerIbrance | $99 | $234,40716 claims |
| NovartisTasigna | $23 | $186,15715 claims |
| Johnson & JohnsonXarelto | $85 | $21,82322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Fayetteville
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.